GRAIL

Pixelgen Technologies Appoints Mostafa Ronaghi to Scientific Advisory Board

Retrieved on: 
Tuesday, April 30, 2024
Stanford University, Membrane, Karolinska Institute, Genomics, Mostafa Ronaghi, Pyrosequencing, Pixelation, Clear Labs, Proteome, Imperial College London, Culture, GRAIL, Drug development, Management

STOCKHOLM, April 30, 2024 /PRNewswire/ -- Pixelgen Technologies announced today the appointment of Mostafa Ronaghi, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • STOCKHOLM, April 30, 2024 /PRNewswire/ -- Pixelgen Technologies announced today the appointment of Mostafa Ronaghi, Ph.D., to its Scientific Advisory Board.
  • "Mostafa is a recognized life sciences visionary leader, with deep expertise in genomics and a tested entrepreneurial spirit," said Pixelgen CEO Simon Fredriksson.
  • "These attributes align well with Pixelgen's mission and culture, and we are honored to have him on our board.
  • "I'm thrilled to join Pixelgen's Scientific Advisory Board and look forward to working with the company's impressive team to continue developing Molecular Pixelation," Ronaghi said.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Doctor of Philosophy, PFS, Paranal Observatory, Table, License, Summit, Investment, ELCC, Progression-free survival, Research, Intraparenchymal hemorrhage, Immunotherapy, Trial of the century, Webcast, Cohort, Forecasting, PD-1, NGS, TKI, Patient, GRAIL, Brain, SMMT, Neoplasm, EGFR, VEGF, GAAP, Royal institute, Neuro, Lung cancer, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.
  • In January 2024, followed by a presentation at ELCC 2024 in March 2024, Akeso announced updates from its Phase II AK112-201 trial data.
  • Also at ELCC 2024, Summit and Akeso highlighted promising ivonescimab Phase II data in NSCLC patients with brain metastases.
  • Operating cash outflow for the three months ended March 31, 2024 and 2023 was $30.1 million and $13.1 million, respectively.

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

Retrieved on: 
Thursday, April 11, 2024
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Doctor of Philosophy, Genomics, Mostafa Ronaghi, Pyrosequencing, Trauma, Clear Labs, NGS, Senior, Translation, GRAIL, SMMT, Organization, Royal institute, Management

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.
  • “We are excited to add Dr. Ronaghi to complement our excellent group of current board members,” stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit.
  • As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to our impressive executive team.”
    Dr. Ronaghi is the Co-Founder and Executive Board Member of Cellanome.
  • “I am very pleased at the opportunity to join Summit’s Board of Directors,” said Dr. Ronaghi.

Aqtual Announces Appointment of Medical, Translational Research and Data Integrity Executives

Retrieved on: 
Tuesday, April 16, 2024
Doctor of Philosophy, Conditional sentence, Cancer, Gilead Sciences, Public health, Blood, Simon Fraser University, Virology, Research, McMaster University, University of California, Davis, Data integrity, Medicine, Molecular biology, Catalog, Disease, Imperial College London, Joint, DNA, Therapy, Public, Patient, GRAIL, MPH, Rheumatoid arthritis, Physician, Translational research, Data analysis, UC, Pharmaceutical industry

HAYWARD, Calif., April 16, 2024 /PRNewswire/ -- Aqtual, Inc., a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology, today announced it has expanded its team to support the development of its molecular diagnostic test for rheumatoid arthritis (RA) therapy selection and its partnering efforts with companies across the pharma and biotech landscape. Signe Fransen has joined as Vice President of Scientific and Medical Affairs, Maggie Louie, Ph.D., has been appointed by Aqtual as Vice President of Translational Research and Strategic Partnerships, and Jason Carlson, MPH, has been brought on as Vice President of Data Integrity and GxP Systems.

Key Points: 
  • Signe Fransen has joined as Vice President of Scientific and Medical Affairs, Maggie Louie, Ph.D., has been appointed by Aqtual as Vice President of Translational Research and Strategic Partnerships, and Jason Carlson, MPH, has been brought on as Vice President of Data Integrity and GxP Systems.
  • We're excited to welcome Signe, Maggie, and Jason to the team to continue this momentum," said Diana Abdueva, Ph.D., co-founder and CEO of Aqtual.
  • Before her appointment at Aqtual, Maggie served as the Vice President of Research at Earli, where she led research initiatives focused on developing a novel synthetic biomarker platform for cancer diagnostics and therapeutics.
  • Mr. Carlson has decades of experience leading cross-functional teams to sustain data integrity, quality, and compliance throughout the product life cycle.

Illumina's planned divestment of GRAIL approved by the European Commission

Retrieved on: 
Friday, April 12, 2024
Civil service commission, European Commission, Sale, DNA, Security (finance), GRAIL, SAN, Risk, Medical device

SAN DIEGO, April 12, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC).

Key Points: 
  • SAN DIEGO, April 12, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC).
  • Illumina continues to explore divesting GRAIL through either a trade sale or a capital markets transaction, each of which are contemplated by the plan approved today.
  • In the event of a capital markets transaction, Illumina must capitalize GRAIL with two-and-a-half years of funding, which is estimated at approximately $1 billion based on GRAIL's long-range plan.
  • Illumina looks forward to working with the EC on approval of final terms consistent with the divestment plan.

Global and Regional MRD Testing Market Analysis Report 2024: Revolutionizing Cancer Patient Management, Rising Consumer Awareness Spurs Demand for MRD Testing - Forecast to 2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Surgery, Medical Devices, Hospitals, Genetics, Health Technology, Biotechnology, Radiology, Health, Oncology, Hospital, PCR, Flow cytometry, Chronic leukemia, Growth, Bone marrow, Incidence, Integration, Patient, NGS, IDT, Research, Health care, Multiple myeloma, Acquisition, Cancer, Medicare, Medicine, Karyotype, MRD, Haematopoietic system, Region, GRAIL, Throttle position sensor, Lymphoma, Polymerase chain reaction, Medical imaging

The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The MRD testing market is driven by several factors, including the expansion in medicare coverage for MRD testing and the administration of solid tumor diagnosis.
  • In recent years, as consumer awareness has grown, there has been an increasing demand for MRD testing.
  • The global MRD testing market is a rapidly growing segment in the healthcare industry, driven by the increasing demand for accurate and sensitive methods to monitor and manage cancer patients.

ILLUMINA ALERT: Bragar Eagel & Squire, P.C. is Investigating Illumina, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, February 27, 2024
Complaint, Acquisition, Icahn, Telephone, News, GRAIL, Defendant, P.C, Cryptocurrency

Our investigation concerns whether the board of directors of Illumina have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Illumina have breached their fiduciary duties to the company.
  • Then, on October 17, 2023, Carl Icahn (“Icahn”) filed a complaint against current and former directors of Illumina, alleging direct and derivative claims of breaches of fiduciary duty.
  • The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.
  • There is no cost or obligation to you.

Getlabs to Add GRAIL's GalleriⓇ Multi-Cancer Early Detection Test to Suite of At-Home Diagnostic Services

Retrieved on: 
Thursday, February 15, 2024
Liver, Collection, Cancer, Prostate, Lung, Survival rate, Breast, Health, Nucleic acid thermodynamics, GRAIL, Patient, DNA, Partnership, Vaccine

MIAMI, Feb. 15, 2024 /PRNewswire/ -- Getlabs , the nationwide leader for at-home diagnostics, today announced that it will be adding GRAIL's GalleriⓇ multi-cancer early detection test to its list of test offerings.

Key Points: 
  • MIAMI, Feb. 15, 2024 /PRNewswire/ -- Getlabs , the nationwide leader for at-home diagnostics, today announced that it will be adding GRAIL's GalleriⓇ multi-cancer early detection test to its list of test offerings.
  • The Galleri test is a significant advancement in multi-cancer early detection screening.
  • "By leveraging our expertise in at-home diagnostic collections, we can greatly expand access to critical cancer screening services.
  • Our partnership with GRAIL represents a step forward in saving lives through early cancer detection."

Curative Insurance Company Adds GRAIL’s Galleri® Test to Member Benefits for Multi-Cancer Early Detection

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Health, Pharmaceutical, Health Technology, Oncology, Partnership, Telehealth, Navigator, DNA, PPO, Prescription, Plasma protein binding, GRAIL, Death, Risk, Cancer, Health care, Liver, Insurance, Health insurance

Curative Insurance Company , a pioneering healthcare services company, and GRAIL , LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced the availability of Galleri®, a multi-cancer early detection (MCED) screening test to eligible insurance plan members.

Key Points: 
  • Curative Insurance Company , a pioneering healthcare services company, and GRAIL , LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced the availability of Galleri®, a multi-cancer early detection (MCED) screening test to eligible insurance plan members.
  • Studies have shown a 75% sensitivity for screening cancers responsible for two-thirds of cancer deaths, rising as high as 80% for the most serious cancers.
  • This is not just about early detection; it's also about empowering our members with the tools to be proactive with their health.
  • To learn more about Curative's revolutionary health insurance plan and how it can benefit employers and employees alike, visit https://curative.com/ .

Manulife Named to 2024 Corporate Knights Global 100

Retrieved on: 
Wednesday, January 17, 2024
Insurance, Vitality, MFC, Health, Agriculture, ESG, Knight, Environment, Investment, TSX, GICS, Manulife, The Global 100, GRAIL, Corporate Knights

Ranking fourth within the Insurance industry, Manulife recognized for performance in sustainable revenues and investments

Key Points: 
  • Ranking fourth within the Insurance industry, Manulife recognized for performance in sustainable revenues and investments
    DAVOS, Switzerland, Jan. 17, 2024 /PRNewswire/ - Manulife (TSX: MFC) has been named to the 2024 Corporate Knights Global 100 rankings as one of the world's most sustainable companies.
  • Manulife's performance in the Global 100 assessment was driven largely through revenues earned from sustainable sources.
  • Corporate Knights also recognized Manulife's strong long-term focus on diversity at the Board and executive management levels, and in connecting sustainability to compensation and performance.
  • In addition to being named to this year's Global 100, Manulife has also been recognized by Corporate Knights as one of Canada's Top 50 Companies for the last three years.